Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2025-02-27 Regulatory Filings
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release from ALK announcing that the US FDA has approved their drug ODACTRA® for treating dust mite allergy in younger children. It details the approval, the significance for the company's strategy, quotes management, references clinical trial data, and lists contact information. Crucially, at the end, it includes a link to an attached file labeled "Selskabsmeddelelse" (Company Announcement) and uses boilerplate language typical of regulatory news distribution platforms (like GlobeNewswire, indicated by the image tags). Since this is an announcement about a regulatory event (FDA approval) and not the full financial report (10-K, IR) or a general earnings release (ER), it fits best as a general Regulatory Filing or Announcement. Given the context of a specific, non-financial regulatory event announcement, 'Regulatory Filings' (RNS) is the most appropriate general category, as it is not a specific financial report, management change, or dividend notice. The document length is relatively short for a full report, supporting the idea that it is an announcement.
2025-02-27 Danish
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release from ALK announcing that the US FDA has approved their drug ODACTRA® for use in young children. This announcement details a specific regulatory event (FDA approval) and provides context on the drug, clinical trials, and future regulatory plans. It is not a comprehensive annual report (10-K), an earnings release (ER), a formal audit report (AR), or a management discussion (MDA). Since it is a specific announcement regarding a regulatory outcome that doesn't fit the defined categories like M&A (TAR) or Capital Change (CAP), it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered elsewhere. Given the nature of the announcement (a specific regulatory milestone), RNS is the most appropriate classification.
2025-02-27 English
Regulatory Filings 2025
Regulatory Filings Classification · 100% confidence The document is a press release from ALK announcing that the US FDA has approved their drug ODACTRA® for a new pediatric indication. It details the approval, quotes executives, mentions clinical trial data, and provides contact information for Investor Relations and Media. This type of announcement, focusing on a specific corporate event (product approval) and often including contact details for IR, fits best under the general category of regulatory or corporate news that isn't a formal financial report (like 10-K or IR) or a specific transaction (like DIRS or POS). Since it is a specific, non-financial regulatory/corporate update, and it is not a standard financial report, it falls under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant corporate news releases that don't fit the other specific codes. It is not an Earnings Release (ER), nor is it a Call Transcript (CT) or a formal Audit Report (AR). Given the nature of the announcement (FDA approval), RNS is the most appropriate general regulatory news category.
2025-02-27 English
Director's Dealing 2025
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff' and references Article 19 of the Market Abuse Regulation (MAR), which mandates reporting of insider transactions by managerial staff. This directly corresponds to the definition of Director's Dealing (DIRS). Although the text mentions an 'Attachment' containing the detailed transactions, the document itself serves as the official notification of these insider trades. Given the specific nature of the content (managerial staff transactions), DIRS is the most appropriate classification over a general RPA or RNS.
2025-02-21 English
Director's Dealing 2025
Director's Dealing Classification · 100% confidence The document explicitly details transactions involving company shares ('B shares') conducted by a member of the managerial staff ('President and CEO', Peter Halling). This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing. The filing code for this is DIRS.
2025-02-21 English
Director's Dealing 2025
Director's Dealing Classification · 98% confidence The document title is "Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer" (Reporting of management transactions with ALK-Abelló A/S' B-shares and related securities). It explicitly references Article 19 of the EU Market Abuse Regulation (MAR), which mandates disclosure of transactions by persons discharging managerial responsibilities (insiders). This directly corresponds to the definition of Director's Dealing (insider trades). Although it mentions an attached file, the core content is the mandatory disclosure of insider transactions, making 'DIRS' the most specific classification over a general 'RPA' or 'RNS'. The document length is very short (1047 chars), but the content is the required regulatory disclosure itself, not just an announcement that a disclosure exists.
2025-02-21 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.